29. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 10 mg to 1200 mg.

30. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

31. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.

33. 32. (Amended) A method of administering a pharmaceutical composition according to claim 1, comprising preparing the pharmaceutical composition comprising of S-tofisopam, pro-drug or pharmaceutically acceptable salt thereof and administering the pharmaceutical composition at a dose of less than 30 mg/kg.

REMARKS

Applicants request acceptance of the claims of the present application in view of the above amendments and the following remarks.

OBJECTIONS

As requested by the Examiner, the following statement has been incorporated at the beginning of the specification: "This application is a continuation of application Serial No. 10/008,516, filed November 8, 2001, now US Patent No. 6,649,607."

As requested by the Examiner, Applicants have amended claim 32 so that claim 32 is a method of administration claim describing the dose at which a pharmaceutical composition comprising S-tofisopam is being administered.

REJECTIONS

Claims 1-5, 28 and 29 have been rejected under 35 U.S.C. 102(a) as being anticipated by the Landry et al reference. The Landry reference teaches the use of (R)-tofisopam for the prevention and treatment of anxiety and anxiety disorders. (R)-tofisopam was found to be the active

isomer of racemic tofisopam in the head twitch assay described in column 21, lines 24-34. (S)-tofisopam was used in the assay merely to show that the (S)-enantiomer was inactive in the assay. Thus, the Landry reference does not anticipate the present invention which describes (S)-tofisopam as an active pharmaceutical ingredient which can be used to effectively treat a disease.

The claims have been further amended to include the limitation that the composition that is being envisioned is one that is pharmaceutically active, rather than a composition that is not pharmaceutically effective.

Furthermore, claim 29 has been amended to delete the language "approximately". None of these amendments introduces new matter.

Double Patenting Rejections

The Examiner has provisionally rejected claims 1-5 and 28-32 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 31 of copending Application No. 10/781,422. Applicants are submitting a terminal disclaimer to obviate the rejection.

The Examiner has nonprovisionally rejected claims 1-5 and 28-32 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5 of US Patent No. 6,649,607. Applicants are submitting a terminal disclaimer to obviate the rejection.

Applicants kindly request that the claims be accepted in view of the remarks and amendments provided above.

Respectfully submitted,



Karen Guerrero
Reg. No. 37,071
Attorney for Applicants
3528 Old Baptist Rd
Collegeville, PA 19426
Tel.: (609) 771-8660 ext. 118

CLAIMS WITH MARKUPS

6. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier.

7. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 85% or more by weight of the total weight of tofisopam.

8. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 90% or more by weight of the total weight of tofisopam.

9. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 95% or more by weight of the total weight of tofisopam.

10. (Amended) The pharmaceutical composition of claim 1 wherein the amound of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.

28. (Amended) The pharmaceutical composition according to claim 1, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, transdermal delivery or oral administration.

32. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from [approximately] 10 mg to 1200 mg.

33. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

34. (Amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.

34. 32. (Amended) A method of administering a pharmaceutical composition according to claim 1, [wherein the amount of] comprising preparing the pharmaceutical composition

comprising S-tofisopam, pro-drug or pharmaceutically acceptable salt [administered is] thereof and a pharmaceutically effective carrier and administering the pharmaceutical composition at a dose of less than 30 mg/kg.